Alectinib
Sign in to save this workspacePrimary targets: ALK, RET · FDA status: FDA Approved
Selectivity scorecard
KISS
95.49
Gini
0.651
CATDS
0.011
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Alectinib. Strongest target: SRPK1 at 99.6% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | SRPK1 | 99.6% | 0.4% |
| 2 | CAMK2D | 99.5% | 0.5% |
| 3 | MSSK1_STK23 | 98.9% | 1.1% |
| 4 | CHK2 | 98.8% | 1.2% |
| 5 | ALK | 98.6% | 1.4% |
| 6 | TYK1_LTK | 98.2% | 1.8% |
| 7 | RET | 97.8% | 2.2% |
| 8 | CAMK2A | 97.7% | 2.3% |
| 9 | PIM3 | 95.1% | 4.9% |
| 10 | PHKG1 | 94.5% | 5.5% |
| 11 | LRRK2 | 94.5% | 5.5% |
| 12 | SRPK2 | 94.4% | 5.6% |
| 13 | FGR | 94.2% | 5.8% |
| 14 | TRKC | 94.2% | 5.8% |
| 15 | CAMKK2 | 93.3% | 6.7% |
| 16 | FLT4_VEGFR3 | 92.8% | 7.2% |
| 17 | LYN | 92.4% | 7.6% |
| 18 | IR | 91.1% | 8.9% |
| 19 | DAPK1 | 89.5% | 10.5% |
| 20 | PHKG2 | 89.3% | 10.7% |
Selectivity landscape
Where Alectinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Alectinib.
Atlas insights for Alectinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 2471.64 | |
| ALLOGRAFT_REJECTION | 8711.78 | |
| ANDROGEN_RESPONSE | 2611.51 | |
| ANGIOGENESIS | 1647.65 | |
| APICAL_JUNCTION | 9137.51 | |
| APICAL_SURFACE | 833.44 | |
| APOPTOSIS | 7116.93 | |
| BILE_ACID_METABOLISM | 1094.68 | |
| CHOLESTEROL_HOMEOSTASIS | 1367.25 | |
| COAGULATION | 981.87 | |
| COMPLEMENT | 5211.83 | |
| DNA_REPAIR | 1680.04 | |
| E2F_TARGETS | 5306.75 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 2483.22 | |
| ESTROGEN_RESPONSE_EARLY | 3901.29 | |
| ESTROGEN_RESPONSE_LATE | 3454.97 | |
| FATTY_ACID_METABOLISM | 651.44 | |
| G2M_CHECKPOINT | 5081.04 | |
| GLYCOLYSIS | 3456.78 | |
| HEDGEHOG_SIGNALING | 1026.36 | |
| HEME_METABOLISM | 1741.94 | |
| HYPOXIA | 4753.76 | |
| IL2_STAT5_SIGNALING | 2634.85 | |
| IL6_JAK_STAT3_SIGNALING | 4659.66 | |
| INFLAMMATORY_RESPONSE | 4817.70 | |
| INTERFERON_ALPHA_RESPONSE | 746.75 | |
| INTERFERON_GAMMA_RESPONSE | 6130.38 | |
| KRAS_SIGNALING_DN | 1532.62 | |
| KRAS_SIGNALING_UP | 3497.05 | |
| MITOTIC_SPINDLE | 5755.94 | |
| MTORC1_SIGNALING | 4351.23 | |
| MYC_TARGETS_V1 | 3335.15 | |
| MYC_TARGETS_V2 | 973.52 | |
| MYOGENESIS | 3473.07 | |
| NOTCH_SIGNALING | 317.64 | |
| OXIDATIVE_PHOSPHORYLATION | 1108.64 | |
| P53_PATHWAY | 3682.54 | |
| PANCREAS_BETA_CELLS | 206.95 | |
| PEROXISOME | 1258.58 | |
| PI3K_AKT_MTOR_SIGNALING | 8899.87 | |
| PROTEIN_SECRETION | 2441.85 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 444.04 | |
| SPERMATOGENESIS | 1362.27 | |
| TGF_BETA_SIGNALING | 1855.98 | |
| TNFA_SIGNALING_VIA_NFKB | 4405.47 | |
| UNFOLDED_PROTEIN_RESPONSE | 1560.29 | |
| UV_RESPONSE_DN | 4911.74 | |
| UV_RESPONSE_UP | 4169.94 | |
| WNT_BETA_CATENIN_SIGNALING | 2368.70 | |
| XENOBIOTIC_METABOLISM | 2160.19 |
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.855 |
| SRR23303752 | — | 0.841 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.836 |
| aMVAC.P_005_TURBT_S223 | — | 0.831 |
| SRR12202498 | — | 0.825 |
Annotations
Sign in to read and post annotations.
Loading…